Search results
Showing 841 to 855 of 2106 results for technology appraisal
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Awaiting development Reference number: GID-TA11975 Expected publication date: TBC
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Awaiting development Reference number: GID-TA11966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11910 Expected publication date: TBC
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]
Awaiting development Reference number: GID-TA11923 Expected publication date: TBC
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026